Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Talphera reported a Q2 net loss of $4.3 million, or $0.06 per share, with cash and investments totaling $17.1 million as of June 30. The NEPHRO CRRT study is 75% enrolled and remains on track for completion by year-end, bolstered by a positive inclusion of nafamostat in draft 2026 KDIGO guidelines. The company regained Nasdaq compliance with the $1 bid price rule and updated market research indicates a 21% increase in estimated annual U.S.
Key figures
- Revenue
- 0
- Net loss
- 4312000
- Rd expenses
- 1690000
- Cash balance
- 17100000
- Sga expenses
- 2234000
- Operating expenses
- 3924000
- Crrt market size increase
- 21%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.